Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Cilostazol
Treatment for Lower extremity peripheral arterial disease
Typical Dosage: 100mg twice daily
Effectiveness
65%
Safety Score
70%
Clinical Trials
4
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
100mg twice daily
Time to Effect
2-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$500
Monitoring:$50
Side Effect Mgmt:$100
Total Annual:$650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$90,000/QALY
QALYs Gained
0.06
Outcome-Based Costs
Cost per Responder
$1,083
Cost per Remission
$1,625
Prescription Access Economics
Annual Societal Loss per Patient
$510
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$500/year
Potential OTC Price
$200/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWWARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Cilostazol in Lower extremity peripheral arterial disease
Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)
NCT01378260COMPLETED
323 participants
OBSERVATIONAL
Bellevue, United States +11 more
Started: Jul 1, 2011
Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
NCT01758874COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 1, 2006